Is Zanubrutinib a chemotherapy drug or a targeted drug?

Zanubrutinib is a prescription medicine indicated for the treatment of adult patients with mantle cell lymphoma(MCL) who have received at least one previous cancer treatment, Waldenström macroglobulinemia, marginal zone lymphoma (MZL), and patients whose disease has relapsed or is unresponsive to treatment and who have received at least one specific type of treatment. It's not known whether zanubrutinib is safe and effective in children.

Zarubrutinib is a targeted drug used to treat certain types ofB-cell non-Hodgkin lymphoma, which are blood cancers that affect B lymphocytes, a type of white blood cell that helps you fight infections. This condition occurs when your body produces too many abnormal B cells. Zabrutinib belongs to a class of drugs called kinase inhibitors, which are second-generation irreversible BTK (Bruton tyrosine kinase) inhibitors that work by blocking the action of a protein called Bruton tyrosine kinase, which signals B cells to grow and multiply. This stops cancer cells from multiplying in your body.

The recommended dose of zanubrutinib is160 mg orally twice daily or 320 mg orally once daily; swallow whole with water, with or without food Do not open, break, or chew capsules. The dose of zanubrutinib should be reduced in patients with severely impaired hepatic function.

The original drug of zanubrutinib has been launched in China and has been included in the medical insurance. The price of each box of 80mg*64 tablets may be around RMB 6,000. The original drug of zanubrutinib marketed overseas is more expensive, and there are currently no generic drugs of zanubrutinib on the market.